Replies to post #212091 on Biotech Values

[mcbio]

ENTA reports preclinical data on EDP-938 RSV inhibitor; phase-1 to begin 4Q17

Has ENTA commented at all on the potential opportunity for an active treatment against RSV (as opposed to vaccine)? The PR notes that each year 75,000 to 125,000 children are hospitalized due to RSV infection. Is it safe to assume that a large portion of this population would be candidates for ENTA's drug (if successfully developed)?

Also, I know you posted on how the potential Synagis successor is not a direct threat to what ENTA is doing (given vaccine vs. active treatment)(#msg-129181634 ), but if the Synagis successor is much more effective than the prior version, couldn't it potentially impact the market opportunity for the ENTA active drug if many more patients get the vaccine and thus less need for an active treatment?